Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 1/20 | 0.61 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.60 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.60 |
| ▸ | TAS1R2 | Q8TE23 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | HTR7 | P34969 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4475562 | 0.97 | DRD4 (0.62) | DRD4TAS1R3TAS1R1TAS1R2MEN1 | |
| SCHEMBL1565272 | 0.92 | DRD4 (0.64) | DRD4TAS1R3TAS1R1TAS1R2CA1 | |
| SCHEMBL4465672 | 0.88 | DRD4 (0.60) | DRD4TAS1R3TAS1R1TAS1R2CA1 | |
| SCHEMBL1564910 | 0.83 | TAS1R3 (0.65) | DRD4TAS1R3TAS1R1TAS1R2CA1 | |
| SCHEMBL4463242 | 0.79 | DRD4 (0.90) | DRD4HTR1AHTR7 | |
| SCHEMBL5923920 | 0.76 | TAS1R3 (0.87) | DRD4TAS1R3TAS1R1TAS1R2MEN1 | |
| SCHEMBL3219218 | 0.76 | TAS1R3 (0.60) | DRD4TAS1R3TAS1R1TAS1R2CA1 | |
| SCHEMBL3730549 | 0.75 | TAS1R3 (0.80) | TAS1R3TAS1R1TAS1R2MEN1KMT2A | |
| SCHEMBL701932 | 0.75 | TAS1R3 (0.80) | TAS1R3TAS1R1TAS1R2MEN1KMT2A | |
| SCHEMBL21214665 | 0.75 | TAS1R3 (0.54) | DRD4TAS1R3TAS1R1TAS1R2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7488730-B2 | N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-phenyl-1-piperazinealkylamide derivatives, and therapeutic use thereof as 5-HT7 receptor ligands | UNIVERSITA DEGLI STUDI DI BARI (IT) | 2009-02-10 | — | — | US | disclosed |
| US-20070117811-A1 | N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-phenyl-1-piperazinealkylamide derivatives, and therapeutic use thereof as 5-HT7 receptor ligands | UNIVERSITA DEGLI STUDI DI BARI (IT) | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117811-A1 | N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-phenyl-1-piperazinealkylamide derivatives, and therapeutic use thereof as 5-HT7 receptor ligands | HTR7, HTR3A, HTR1E | DRD4 404/4885TAS1R3 795/4885TAS1R1 891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.